Eisai, Biogen move Alzheimer’s treatment into Phase III
Eisai and Biogen’s BAN2401 is to be put into Phase III trial for patients with early Alzheimer’s disease.
Read More
Tag: BAN2401
Eisai, Biogen’s Alzheimer’s candidate shows promise in PhII trial
At last some good news for Alzheimer’s research, as Eisai and Biogen’s experimental anti beta-amyloid therapy BAN2401 hit targets in a Phase II trial in patients with the disease.
Read More
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
